Long-Term Administration of a Low-Molecular-Weight Heparin Contributed to Successful Treatment in a Patient With Primary Mediastinal Large B-Cell Lymphoma and Venous Thromboembolism

Abstract

The case of a 16-year-old girl with primary mediastinal large B-cell lymphoma who had thrombosis in the brachiocephalic, subclavian, and internal jugular veins at presentation is reported. MACOP-B chemotherapy plus radiation therapy could be the first-line strategy, but MACOP-B increases the risk of thrombosis. Although an effective method for initial treatment of venous thromboembolism (VTE) in cancer patients has not been established, recent studies revealed that the administration of a low-molecular-weight heparin (LMWH) was effective for secondary prevention of VTE. Therefore, the patient in this case was treated with MACOP-B plus rituximab followed by radiation therapy, and an LMWH was administered through the course of treatment. She achieved complete remission and never suffered from VTE. This case suggests that long-term administration of an LMWH contributes to the primary improvement and secondary prevention of VTE even in patients who are at high risk for thrombosis.

Keywords

low-molecular-weight heparin venous thromboembolism primary mediastinal large B-cell lymphoma MACOP-B

References

Lip GY , Chin BS , Blann AD Cancer and prothrombotic state. Lancet Oncol. 2002;3:27-34.

Clarke CS , Otridge BW , Carney DN Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma. Cancer. 1990;66:2027-2030.

Ottinger H. , Belka C. , Kozole G. , et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non-Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol. 1995;54:186-194.

Lee AY , Levine MN , Baker RI , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.

Zinzani PL , Martelli M. , Bertini M. , et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258-1264.

Dzhumabaeva BT , Kremenetskaia AM , Vasil'ev SA , et al. Possibility of diagnosis and treatment of thrombotic complications in primary mediastinal B-cell lymphosarcoma. Ter Arkh. 2004;76:50-54.

Klimo P. , Connors JM MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596-602.

van Besien K. , Ha CS , Murphy S. , et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178-1184.

Trousseau A. Phelegmasia alba dolens. In: Clinique medicale de 1'Hotel-Dieu de Paris. Paris, France: Bailliere ; 1865:654.

10.

Levine MN , Lee AY Risk assessment and primary VTE prevention in the cancer patient. Pathophysiol Haemost Thromb. 2003;33(suppl 1):36-41.

11.

Bick RL Cancer-associated thrombosis. N Engl J Med. 2003;349:109-111.

12.

Coiffier B. , Lepage E. , Briere J. , et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.

13.

Hull RD , Pineo GF , Brant RF , et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119:1062-1072.

14.

van Dongen CJ , van den Belt AG , Prins MH , Lensing AW Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism . Cochrane Database Syst Rev. 2004;(4):CD001100.